Bariatric Surgery Outperforms Semaglutide for Weight Loss and Diabetes Remission at 2 Years | Research

The takeaway

In a Swedish registry study comparing 606 surgical patients to 997 semaglutide users with type 2 diabetes, bariatric surgery achieved 26.4% weight loss vs 5.2% with semaglutide and 63% vs 14% diabetes remission at 2 years.

26.4% vs 5.2% weight loss
Bariatric surgery achieved over 5 times more weight loss than semaglutide at 2 years, with 63% diabetes remission vs 14% — though these represent different treatment modalities with different risk profiles

What the researchers found

At 2 years: bariatric surgery achieved 26.4% ± 8.83% total weight loss vs 5.2% ± 7.87% with semaglutide (p<0.001). Mean HbA1c: 42.3 ± 11.18 after surgery vs 50.7 ± 12.48 after semaglutide (p<0.001). Complete diabetes remission: 63.0% with surgery vs 13.9% with semaglutide (p<0.001).

Why it matters

As semaglutide becomes the dominant medical weight loss treatment, patients and clinicians need realistic comparisons. This study provides the most direct head-to-head comparison available, showing that while semaglutide works, surgery remains substantially more effective for both weight loss and diabetes remission — an important consideration for treatment planning.

The numbers in context

Patients treated for ≥2 years. Propensity score matching included age, sex, HbA1c, diabetes duration, and other factors.

How the study worked

Propensity score-matched cohort study using the Scandinavian Obesity Surgery Registry and Swedish National Diabetes Registry. 606 surgical patients matched 1:1-2 with 997 semaglutide users starting treatment 2018-2020. Matching variables: age, sex, HbA1c, diabetes duration, insulin use, comorbidities, cancer history. Residual imbalances in GFR and BMI were statistically adjusted.

Who was studied

Swedish adults with type 2 diabetes and obesity, matched by propensity score

What this study cannot tell us

Observational registry study — not a randomized trial. Despite propensity matching, residual confounding likely exists (surgical patients may be more motivated, have different baseline characteristics). Semaglutide doses used in 2018-2020 may have been lower than current protocols. The 5.2% weight loss with semaglutide is lower than seen in clinical trials, possibly reflecting real-world adherence issues. Surgery types varied (sleeve gastrectomy, Roux-en-Y, etc.). No data on adverse events or quality of life.

How to read the evidence

Moderate evidence from a large, well-designed propensity-matched registry study. Stronger than observational data alone but weaker than an RCT due to potential residual confounding and selection bias.

When this study was published

Published in 2024 with 2018-2020 treatment data. Semaglutide dosing and practice patterns may have evolved since the study period.

The bigger picture

The obesity treatment landscape is shifting as GLP-1 drugs gain popularity, and some patients are choosing medication over surgery. This study puts the effectiveness gap in perspective — surgery is about 5 times more effective for weight loss. However, the comparison isn't straightforward: surgery is a one-time procedure while semaglutide requires ongoing use, surgery has operative risks, and semaglutide doses in the study period may not reflect current higher-dose protocols.

Questions still open

Would higher semaglutide doses (2.4 mg) or newer agents like tirzepatide narrow the gap with surgery?
What do the 5-year and 10-year comparisons look like, given that weight regain occurs with both treatments?

Common questions

Is semaglutide a good alternative to weight loss surgery?

Semaglutide helps, but this study shows it achieves about one-fifth the weight loss of surgery (5.2% vs 26.4%). For patients who are not candidates for or don't want surgery, semaglutide provides meaningful but more modest benefits. For maximum weight loss and diabetes remission, surgery remains superior — but it carries surgical risks and is irreversible.

Why was the weight loss with semaglutide lower than in clinical trials?

Clinical trials typically use higher doses (2.4 mg for obesity), have strict monitoring, and selected motivated participants. This real-world study used diabetes-dose semaglutide (up to 1.0 mg), and patients may have had variable adherence, different dietary support, and other real-world factors that reduce effectiveness compared to controlled trial settings.

Read the original research

Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.

Diabetes, obesity & metabolism, 26(12), 5812-5818

View on PubMed ↗Publisher’s paper ↗

Citation

Stenberg, Erik; Cao, Yang; Ottosson, Johan; Hedberg, Suzanne; Näslund, Erik. (2024). Glycaemic and weight effects of metabolic surgery or semaglutide in diabetes dosage for patients with type 2 diabetes.. Diabetes, obesity & metabolism, 26(12), 5812-5818. https://doi.org/10.1111/dom.15952